Brind.

Quoin Pharmaceuticals Ltd., which focuses on rare and orphan diseases, is developing investigational candidate QRX003 for Netherton Syndrome. Denise Carter serves as Co-Founder and COO.

4 reports, 1 independent Updated Aug 21
Gone quiet
Reports
4
Developments
5
Repetition
25%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Quoin Pharmaceuticals Ltd., which focuses on rare and orphan diseases, is developing investigational candidate QRX003 for Netherton Syndrome. Denise Carter serves as Co-Founder and COO.

Who's involved

What this event is mainly about
Denise Carter

How it developed

Newest first. Tap a step to see who reported it.
  1. Quoin Pharmaceuticals received Rare Pediatric Disease and Orphan Drug status from FDA and EMA for its Netherton Syndrome candidate.Sub-event
  2. Quoin Pharmaceuticals Ltd. featured Mandy Aldwin-Easton, who lives with Netherton Syndrome, in its NETHERTON NOW video series.Sub-event
  3. Quoin Pharmaceuticals is developing investigational candidate QRX003 for Netherton Syndrome.1 source
  4. Quoin Pharma announces leadership changes, naming Myers as CEO and Lawlor as CFO.1 source
  5. Quoin announced plans to self-commercialize QRX003 in Western Europe.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireQuoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome ASHBURN, Va., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceutical
  • GlobeNewswireQuoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or
  • GlobeNewswireQuoin Pharmaceuticals Provides Product Portfolio Update Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle
  • Unknown outlet